USA Infliximab and biosimilar Market Professional Research Report 2022-2027, Segmented by Players, Types, End-Users in Major Regions

  • REPORT SUMMARY
  • TABLE OF CONTENTS
  • Infliximab (trade names Remicade among others) is a chimeric monoclonal antibody biologic drug that works against tumor necrosis factor alpha (TNF-?) and is used to treat autoimmune diseases.

    This report offers an overview of the market trends, drivers, and barriers with respect to the USA Infliximab and biosimilar market. It also provides a detailed overview of the market of different regions across West USA, South USA, Middle West USA, Northeast USA. The report deeply analyzes type and application in the USA Infliximab and biosimilar market. Detailed analysis of key players, along with key growth strategies adopted by Infliximab and biosimilar industry, the PEST and SWOT analysis are also included. In short, the report will provide a comprehensive view of the industry's development and features.

    By Player:

    • Pfizer

    • Merck and Co

    By Type:

    • Infliximab

    • infliximab-dyyb

    • infliximab-abda

    By End-User:

    • Crohn's Disease

    • Pediatric Crohn's Disease

    • Ulcerative Colitis

    • Rheumatoid Arthritis

    • Ankylosing Spondylitis

    • Psoriatic Arthritis

    • Plaque Psoriasis

    By Region:

    • West USA

    • South USA

    • Middle West USA

    • Northeast USA

  • TABLE OF CONTENT

    1 Report Overview

    • 1.1 Product Definition and Scope

    • 1.2 PEST (Political, Economic, Social and Technological) Analysis of Infliximab and biosimilar Market

    • 1.3 Market Segment by Type

      • 1.3.1 USA Infliximab and biosimilar Market Size and Growth Rate of Infliximab from 2016 to 2027

      • 1.3.2 USA Infliximab and biosimilar Market Size and Growth Rate of infliximab-dyyb from 2016 to 2027

      • 1.3.3 USA Infliximab and biosimilar Market Size and Growth Rate of infliximab-abda from 2016 to 2027

    • 1.4 Market Segment by Application

      • 1.4.1 USA Infliximab and biosimilar Market Size and Growth Rate of Crohn's Disease from 2016 to 2027

      • 1.4.2 USA Infliximab and biosimilar Market Size and Growth Rate of Pediatric Crohn's Disease from 2016 to 2027

      • 1.4.3 USA Infliximab and biosimilar Market Size and Growth Rate of Ulcerative Colitis from 2016 to 2027

      • 1.4.4 USA Infliximab and biosimilar Market Size and Growth Rate of Rheumatoid Arthritis from 2016 to 2027

      • 1.4.5 USA Infliximab and biosimilar Market Size and Growth Rate of Ankylosing Spondylitis from 2016 to 2027

      • 1.4.6 USA Infliximab and biosimilar Market Size and Growth Rate of Psoriatic Arthritis from 2016 to 2027

      • 1.4.7 USA Infliximab and biosimilar Market Size and Growth Rate of Plaque Psoriasis from 2016 to 2027

    • 1.5 Market Segment by Regions

      • 1.5.1 West USA Infliximab and biosimilar Consumption Market Size and Growth Rate from 2016 to 2027

      • 1.5.2 South USA Infliximab and biosimilar Consumption Market Size and Growth Rate from 2016 to 2027

      • 1.5.3 Middle West USA Infliximab and biosimilar Consumption Market Size and Growth Rate from 2016 to 2027

      • 1.5.4 Northeast USA Infliximab and biosimilar Consumption Market Size and Growth Rate from 2016 to 2027

    2 Market Trends and Competitive Landscape

    • 2.1 Market Trends and Dynamics

      • 2.1.1 Market Challenges and Restraints

      • 2.1.2 Market Opportunities and Potentials

      • 2.1.3 Mergers and Acquisitions

    • 2.2 Competitive Landscape Analysis

      • 2.2.1 Industrial Concentration Analysis

      • 2.2.2 Porter's Five Forces Analysis of the Industry

      • 2.2.3 SWOT Analysis for New Entrants

    • 2.3 Coronavirus (COVID-19) Distribution and its Impact on the Industry

    3 Segmentation of Infliximab and biosimilar Market by Types

    • 3.1 Products Development Trends of Different Types

    • 3.2 Products Types of Major Vendors

    • 3.3 Competitive Landscape Analysis of Different Types

    • 3.4 Market Size of Infliximab and biosimilar by Major Types

      • 3.4.1 Market Size and Growth Rate of Infliximab

      • 3.4.2 Market Size and Growth Rate of infliximab-dyyb

      • 3.4.3 Market Size and Growth Rate of infliximab-abda

    4 Segmentation of Infliximab and biosimilar Market by End-Users

    • 4.1 Downstream Client Analysis by End-Users

    • 4.2 Competitive Landscape Analysis of Different End-Users

    • 4.3 Market Potential Analysis of Different End-Users

    • 4.4 Market Size of Infliximab and biosimilar by Major End-Users

      • 4.4.1 Market Size and Growth Rate of Infliximab and biosimilar in Crohn's Disease

      • 4.4.2 Market Size and Growth Rate of Infliximab and biosimilar in Pediatric Crohn's Disease

      • 4.4.3 Market Size and Growth Rate of Infliximab and biosimilar in Ulcerative Colitis

      • 4.4.4 Market Size and Growth Rate of Infliximab and biosimilar in Rheumatoid Arthritis

      • 4.4.5 Market Size and Growth Rate of Infliximab and biosimilar in Ankylosing Spondylitis

      • 4.4.6 Market Size and Growth Rate of Infliximab and biosimilar in Psoriatic Arthritis

      • 4.4.7 Market Size and Growth Rate of Infliximab and biosimilar in Plaque Psoriasis

    5 Market Analysis by Regions

    • 5.1 USA Infliximab and biosimilar Production Analysis by Regions

    • 5.2 USA Infliximab and biosimilar Consumption Analysis by Regions

    • 5.3 Coronavirus (COVID-19) Impact on USA Economy

    6 West USA Infliximab and biosimilar Landscape Analysis

    • 6.1 West USA Infliximab and biosimilar Landscape Analysis by Major Types

    • 6.2 West USA Infliximab and biosimilar Landscape Analysis by Major End-Users

    7 South USA Infliximab and biosimilar Landscape Analysis

    • 7.1 South USA Infliximab and biosimilar Landscape Analysis by Major Types

    • 7.2 South USA Infliximab and biosimilar Landscape Analysis by Major End-Users

    8 Middle West USA Infliximab and biosimilar Landscape Analysis

    • 8.1 Middle West USA Infliximab and biosimilar Landscape Analysis by Major Types

    • 8.2 Middle West USA Infliximab and biosimilar Landscape Analysis by Major End-Users

    9 Northeast USA Infliximab and biosimilar Landscape Analysis

    • 9.1 Northeast USA Infliximab and biosimilar Landscape Analysis by Major Types

    • 9.2 Northeast USA Infliximab and biosimilar Landscape Analysis by Major End-Users

    10 Major Players Profiles

      • 10.1 Pfizer

        • 10.1.1 Pfizer Company Profile and Recent Development

        • 10.1.2 Market Performance

        • 10.1.3 Product and Service Introduction

      • 10.2 Merck and Co

        • 10.2.1 Merck and Co Company Profile and Recent Development

        • 10.2.2 Market Performance

        • 10.2.3 Product and Service Introduction

    The List of Tables and Figures

    • Figure Product Picture

    • Figure USA Infliximab and biosimilar Market Size and Growth Rate of Infliximab from 2016 to 2027

    • Figure USA Infliximab and biosimilar Market Size and Growth Rate of infliximab-dyyb from 2016 to 2027

    • Figure USA Infliximab and biosimilar Market Size and Growth Rate of infliximab-abda from 2016 to 2027

    • Figure Market Share by Type in 2016

    • Figure Market Share by Type in 2020

    • Figure Market Share by Type in 2027

    • Figure USA Infliximab and biosimilar Market Size and Growth Rate of Crohn's Disease from 2016 to 2027

    • Figure USA Infliximab and biosimilar Market Size and Growth Rate of Pediatric Crohn's Disease from 2016 to 2027

    • Figure USA Infliximab and biosimilar Market Size and Growth Rate of Ulcerative Colitis from 2016 to 2027

    • Figure USA Infliximab and biosimilar Market Size and Growth Rate of Rheumatoid Arthritis from 2016 to 2027

    • Figure USA Infliximab and biosimilar Market Size and Growth Rate of Ankylosing Spondylitis from 2016 to 2027

    • Figure USA Infliximab and biosimilar Market Size and Growth Rate of Psoriatic Arthritis from 2016 to 2027

    • Figure USA Infliximab and biosimilar Market Size and Growth Rate of Plaque Psoriasis from 2016 to 2027

    • Figure Market Share by End-User in 2016

    • Figure Market Share by End-User in 2020

    • Figure Market Share by End-User in 2027

    • Figure West USA Infliximab and biosimilar Consumption Market Size and Growth Rate from 2016 to 2027

    • Figure South USA Infliximab and biosimilar Consumption Market Size and Growth Rate from 2016 to 2027

    • Figure Middle West USA Infliximab and biosimilar Consumption Market Size and Growth Rate from 2016 to 2027

    • Figure Northeast USA Infliximab and biosimilar Consumption Market Size and Growth Rate from 2016 to 2027

    • Figure Development Trends and Industry Dynamics of Infliximab and biosimilar Industry

    • Figure Market Challenges and Restraints

    • Figure Market Opportunities and Potentials

    • Table Mergers and Acquisition

    • Figure Market Share of TOP 3 Players in 2019

    • Figure Market Share of TOP 5 Players in 2019

    • Figure Market Share of TOP 6 Players from 2016 to 2020

    • Figure Porter's Five Forces Analysis

    • Figure New Entrant SWOT Analysis

    • Figure Coronavirus (COVID-19) Distribution Map of USA

    • Table Coronavirus (COVID-19) Impact on the Industry

    • Figure Specifications of Different Types of Infliximab and biosimilar

    • Figure Development Trends of Different Types

    • Table Products Types of Major Vendors

    • Figure Competitive Landscape Analysis of Different Types

    • Table Consumption of Infliximab and biosimilar by Different Types from 2016 to 2027

    • Table Consumption Share of Infliximab and biosimilar by Different Types from 2016 to 2027

    • Figure Market Size and Growth Rate of Infliximab

    • Figure Market Size and Growth Rate of infliximab-dyyb

    • Figure Market Size and Growth Rate of infliximab-abda

    • Table Downstream Client Analysis by End-Users

    • Figure Competitive Landscape Analysis of Different End-Users

    • Table Market Potential Analysis of Different End-Users

    • Figure Consumption of Infliximab and biosimilar by Different End-Users from 2016 to 2027

    • Table Consumption Share of Infliximab and biosimilar by Different End-Users from 2016 to 2027

    • Figure Market Size and Growth Rate of Crohn's Disease

    • Figure Market Size and Growth Rate of Pediatric Crohn's Disease

    • Figure Market Size and Growth Rate of Ulcerative Colitis

    • Figure Market Size and Growth Rate of Rheumatoid Arthritis

    • Figure Market Size and Growth Rate of Ankylosing Spondylitis

    • Figure Market Size and Growth Rate of Psoriatic Arthritis

    • Figure Market Size and Growth Rate of Plaque Psoriasis

    • Table USA Infliximab and biosimilar Production by Regions

    • Table USA Infliximab and biosimilar Production Share by Regions

    • Figure USA Infliximab and biosimilar Production Share by Regions in 2016

    • Figure USA Infliximab and biosimilar Production Share by Regions in 2021

    • Figure USA Infliximab and biosimilar Production Share by Regions in 2027

    • Table USA Infliximab and biosimilar Consumption by Regions

    • Table USA Infliximab and biosimilar Consumption Share by Regions

    • Figure USA Infliximab and biosimilar Consumption Share by Regions in 2016

    • Figure USA Infliximab and biosimilar Consumption Share by Regions in 2021

    • Figure USA Infliximab and biosimilar Consumption Share by Regions in 2027

    • Table West USA Infliximab and biosimilar Consumption by Types from 2016 to 2027

    • Table West USA Infliximab and biosimilar Consumption Share by Types from 2016 to 2027

    • Figure West USA Infliximab and biosimilar Consumption Share by Types in 2016

    • Figure West USA Infliximab and biosimilar Consumption Share by Types in 2021

    • Figure West USA Infliximab and biosimilar Consumption Share by Types in 2027

    • Table West USA Infliximab and biosimilar Consumption by End-Users from 2016 to 2027

    • Table West USA Infliximab and biosimilar Consumption Share by End-Users from 2016 to 2027

    • Figure West USA Infliximab and biosimilar Consumption Share by End-Users in 2016

    • Figure West USA Infliximab and biosimilar Consumption Share by End-Users in 2021

    • Figure West USA Infliximab and biosimilar Consumption Share by End-Users in 2027

    • Table South USA Infliximab and biosimilar Consumption by Types from 2016 to 2027

    • Table South USA Infliximab and biosimilar Consumption Share by Types from 2016 to 2027

    • Figure South USA Infliximab and biosimilar Consumption Share by Types in 2016

    • Figure South USA Infliximab and biosimilar Consumption Share by Types in 2021

    • Figure South USA Infliximab and biosimilar Consumption Share by Types in 2027

    • Table South USA Infliximab and biosimilar Consumption by End-Users from 2016 to 2027

    • Table South USA Infliximab and biosimilar Consumption Share by End-Users from 2016 to 2027

    • Figure South USA Infliximab and biosimilar Consumption Share by End-Users in 2016

    • Figure South USA Infliximab and biosimilar Consumption Share by End-Users in 2021

    • Figure South USA Infliximab and biosimilar Consumption Share by End-Users in 2027

    • Table Middle West USA Infliximab and biosimilar Consumption by Types from 2016 to 2027

    • Table Middle West USA Infliximab and biosimilar Consumption Share by Types from 2016 to 2027

    • Figure Middle West USA Infliximab and biosimilar Consumption Share by Types in 2016

    • Figure Middle West USA Infliximab and biosimilar Consumption Share by Types in 2021

    • Figure Middle West USA Infliximab and biosimilar Consumption Share by Types in 2027

    • Table Middle West USA Infliximab and biosimilar Consumption by End-Users from 2016 to 2027

    • Table Middle West USA Infliximab and biosimilar Consumption Share by End-Users from 2016 to 2027

    • Figure Middle West USA Infliximab and biosimilar Consumption Share by End-Users in 2016

    • Figure Middle West USA Infliximab and biosimilar Consumption Share by End-Users in 2021

    • Figure Middle West USA Infliximab and biosimilar Consumption Share by End-Users in 2027

    • Table Northeast USA Infliximab and biosimilar Consumption by Types from 2016 to 2027

    • Table Northeast USA Infliximab and biosimilar Consumption Share by Types from 2016 to 2027

    • Figure Northeast USA Infliximab and biosimilar Consumption Share by Types in 2016

    • Figure Northeast USA Infliximab and biosimilar Consumption Share by Types in 2021

    • Figure Northeast USA Infliximab and biosimilar Consumption Share by Types in 2027

    • Table Northeast USA Infliximab and biosimilar Consumption by End-Users from 2016 to 2027

    • Table Northeast USA Infliximab and biosimilar Consumption Share by End-Users from 2016 to 2027

    • Figure Northeast USA Infliximab and biosimilar Consumption Share by End-Users in 2016

    • Figure Northeast USA Infliximab and biosimilar Consumption Share by End-Users in 2021

    • Figure Northeast USA Infliximab and biosimilar Consumption Share by End-Users in 2027

    • Table Company Profile and Development Status of Pfizer

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Pfizer

    • Figure Sales and Growth Rate Analysis of Pfizer

    • Figure Revenue and Market Share Analysis of Pfizer

    • Table Product and Service Introduction of Pfizer

    • Table Company Profile and Development Status of Merck and Co

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Merck and Co

    • Figure Sales and Growth Rate Analysis of Merck and Co

    • Figure Revenue and Market Share Analysis of Merck and Co

    • Table Product and Service Introduction of Merck and Co


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.